Movano Health Plans Response Submission to FDA Next Week as Part of EvieMED Final Review Phase

A successful response to requests for additional information would bring the Company one step closer to introducing this pioneering healthcare product to the marketPLEASANTON, Calif., Oct. 24, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it plans to submit updated responses next week to all clarifying questions that it recently received from the FDA as part of the final phase of the Company's 510(k) application review. The Company secured a positive resolution this summer after res ...